Drug Trial Radar · NCT02468674
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
Last checked: Nov 19, 2026Latest source record: Jun 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Jul 22, 2015
Primary completion
Dec 3, 2018
Study completion Dec 3, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
Conditions
- Sarcopenia
Interventions
bimagrumabDrug
bimagrumab low dose bimagrumab moderate dose bimagrumab high dose Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
PlaceboDrug
Placebo Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49Time frame: Week 49
- Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49Time frame: Week 49
Locations
30 sites in 12 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Miami Lakes, Florida
Novartis Investigative Site
Gainesville, Georgia
Novartis Investigative Site
Spartanburg, South Carolina
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Madison, Wisconsin
Novartis Investigative Site
St Albans, Victoria, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Copenhagen NV, Denmark
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Ōbu, Aichi-ken, Japan
Novartis Investigative Site
Toyohashi, Aichi-ken, Japan
Novartis Investigative Site
Mizunami, Gifu, Japan
Novartis Investigative Site
Nara, Nara, Japan
Novartis Investigative Site
Kawachi-Nagano, Osaka, Japan
Novartis Investigative Site
Kitaadachigun Inamachi, Saitama, Japan
Novartis Investigative Site
Kitamoto, Saitama, Japan
Novartis Investigative Site
Kiyose, Tokyo, Japan
Novartis Investigative Site
Koto-ku, Tokyo, Japan
Novartis Investigative Site
tabashi City, Tokyo, Japan
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Yaroslavl, Russia
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea
Novartis Investigative Site
Albacete, Castille-La Mancha, Spain
Novartis Investigative Site
Getafe, Madrid, Spain
Novartis Investigative Site
Geneva, Switzerland
Novartis Investigative Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.